#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Giant cell tumour of tendon sheath PIK3CA-activated mutation Germ cell cancer B-cell lymphoma refractory Neuroblastoma ABO haemolytic disease of newborn Mastocytosis Neoplasm IgA nephropathy Congenital aplastic anaemia Short-bowel syndrome Endometrial adenocarcinoma Pemphigoid Pelizaeus-Merzbacher disease Glioblastoma More trials…

    Learn about Rare Diseases

    Leiomyosarcoma – Trials in Disease Anaplastic thyroid cancer Basal cell naevus syndrome – Diagnostics Breast angiosarcoma metastatic – Trials in Disease Medulloblastoma recurrent – Treatment Haemolytic uraemic syndrome – Treatment Gastrointestinal stromal tumour – Life with Disease Adrenocortical carcinoma Systemic sclerosis pulmonary – Trials in Disease Turner’s syndrome – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Volrustomig TUB-030 DAPIGLUTIDE Neob Bupivacaine Messenger Rna Encoding Cas9 Caspofungin Grwd5769 Belzupacap Sarotalocan Art0380 Mesilate 7-Ethyl-10-Hydroxycamptothecin Resmetirom Rupatadine Quercus Robur Pollen Extract IHMA-2121908-1 Biotin HALOBETASOL PROPIONATE Citric Acid ISPAGHULA HUSK Mepolizumab More therapies…

    Learn about Your Condition

    Tumour of ampulla of Vater Hysterectomy Neuromuscular scoliosis Colon cancer metastatic Blood iron increased Thromboangiitis obliterans Penile cancer Peritoneal abscess Arthroscopy Anal cancer recurrent Electronic cigarette user Chronic kidney disease Ocular lymphoma Prodromal Alzheimer's disease Adenomyosis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Simplex Kft.

Simplex Kft.

Facan Utca 2, Sostohegy, Nyiregyhaza, 4481, Hungary

Want to learn more about this study or check if you can participate? Contact us.

  • Comparison of CHF5993 (glycopyrronium bromide, formoterol fumarate dihydrate, and beclometasone dipropionate) and a drug combination for patients with mild to moderate asthma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Asthma
    Investigated Drugs:
    • Beclometasone Dipropionate Anhydrous
    • Glycopyrronium Bromide
    • Beclometasone Dipropionate
    Bulgaria Czechia Germany Hungary Latvia Poland +2

  • Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

    Recruiting

    3 1
    Bulgaria Czechia Denmark France Germany Greece +7

  • Study of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) to Reduce Disease Flare-ups

    Recruiting

    3 1 1
    Investigated Diseases:
    • Chronic obstructive pulmonary disease
    Investigated Drugs:
    • Tezepelumab
    Belgium Bulgaria Denmark France Greece Hungary +3

  • Study on Baxdrostat and Dapagliflozin for Preventing Heart Failure in Patients at High Risk

    Recruiting

    3 1 1
    Investigated Drugs:
    • Baxdrostat
    • Dapagliflozin
    Bulgaria Czechia Denmark France Germany Greece +8

  • Study on the Effects of Budesonide, Glycopyrronium, and Formoterol Fumarate for Patients with Chronic Obstructive Pulmonary Disease (COPD)

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Chronic obstructive pulmonary disease
    Investigated Drugs:
    • Glycopyrronium Bromide
    • Salbutamol
    • Budesonide
    Austria Bulgaria Czechia Denmark Finland France +10

  • A study testing tozorakimab for long-term treatment of chronic obstructive pulmonary disease in former smokers with repeated flare-ups

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Chronic obstructive pulmonary disease
    Investigated Drugs:
    • Tozorakimab
    • Salbutamol
    Belgium Bulgaria Czechia Denmark Finland France +11

  • Study of Tozorakimab for Patients with Chronic Obstructive Pulmonary Disease Who Have Symptoms and a History of Flare-ups

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Chronic obstructive pulmonary disease
    Investigated Drugs:
    • Tozorakimab
    • Salbutamol Sulfate
    Belgium Bulgaria Czechia Denmark Finland Hungary +5

  • Study of AZD0780 in patients with high cholesterol and heart disease or risk of heart disease to lower bad cholesterol levels

    Not recruiting

    3 1
    Bulgaria Czechia Germany Hungary Poland Slovakia +1

  • Study on the Effectiveness and Safety of CHF 5993 Compared to CHF 1535 for Patients with Chronic Obstructive Pulmonary Disease (COPD)

    Not recruiting

    3 1
    Investigated Diseases:
    • Chronic obstructive pulmonary disease
    Investigated Drugs:
    • Beclometasone Dipropionate Anhydrous
    • Glycopyrronium Bromide
    • Formoterol Fumarate Dihydrate
    Bulgaria Czechia Hungary Poland Romania

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!